Varenicline Oxalate

ST. LOUIS--(BUSINESS WIRE)-- EyeCare Partners (ECP), the nation’s leading provider of clinically integrated eye care, today announced more than 20 of its physicians will be presenting the latest innovative modalities and mechanisms across a wide range of ophthalmic disciplines in 90 sessions at the American Society of Cataract and Refractive Surgery (ASCRS). The annual meeting will take place May 5-8, 2023, in San Diego. The breadth of topics being presented at ASCRS by ECP physicians emphasizes the company’s culture of innovation and continuous learning. It also underscores the possibility of a career “third pathway” which allows physicians to conduct industry-leading research while also continuing to build a clinical practice. “EyeCare Partners has a strong representation of ophthalmologists presenting research at ASCRS this year, in addition to one of our specialists, Dr. Elizabeth Yeu, serving as the incoming president of ASCRS,” said David Clark, CEO of EyeCare Partners. “We are committed to elevating eye care, and we are proud to work with many ophthalmologists who are leading educators in their field and committed to advancing eye care through innovation and clinical research.” Select ECP physician presentations at ASCRS include: “Prospective Evaluation of Eye Drop Self-Administration Accuracy in a Real-World Patient Population” – Alison Early, M.D., Cincinnati Eye Institute “Cardiovascular Effects of Immunosuppression for Ocular Surface Stem Cell Transplantation” – Albert Y. Cheung, M.D., Virginia Eye Consultants “Treatment of Corneal Neovascularization Prior to Deep Anterior Lamellar Keratoplasty” – Albert Cheung, M.D., Virginia Eye Consultants “Corneal Healing after Cenegermin Treatment in Patients with Stage 1 Neurotrophic Keratopathy” – Gregg Berdy M.D., Ophthalmology Associates “Cryopreserved Amniotic Membrane during Pterygium Excision: Health Economic Opportunity Analysis” – Neel Desai, M.D., Eye Institute of West Florida “Surgeon and Patient Experience Following Toric IOL Alignment with and without a Novel Ocular Registration-Guided Graphical Overlay System” – Robert Weinstock, M.D., Eye Institute of West Florida “Retrospective Assessment of the Routine Use of Loteprednol Etabonate Gel 0.38% Following LASIK and PRK Surgery” – Joseph Gira, M.D., Ophthalmology Associates “Interim Assessment of Safety & Efficacy of Human Corneal Endothelial Cell Therapy for Corneal Edema Secondary to Endothelial Dysfunction” – Edward Holland, M.D., Cincinnati Eye Institute “A Trifocal Lens with New Hydrophobic Acrylic Lens Material: A Study of Patient Satisfaction and Visual Performance” – Michael Jones, M.D., Quantum Vision Centers “EW-6 Be part of History in the making…The Big Bang in surgical visualization systems has arrived” – Caroline Watson, M.D., Alabama Vision Center, John Kitchens, M.D., Retina Associates of Kentucky “Axial Length Related Visual Outcomes in an Extended Depth of Focus Lens Implantation” – Rohit Krishna, M.D., Sabates Eye Centers “Sublingual Midazolam and Ketamine for Surgical Sedation, a Multicenter, Double Masked, Randomized Controlled Trial” – Michael Nordlund, M.D., Ph.D., Cincinnati Eye Institute “Visual Outcomes of the Tecnis Symfony Lens in Patients with Ocular Hypertension and Mild to Moderate Glaucoma” – Constance Okeke, M.D., Virginia Eye Consultants “IC-124 Management of Complications Encountered during Cataract Surgery” – Robert Osher, M.D., Cincinnati Eye Institute “STL-2 Iris Prothesis” – Samantha Schockman, M.D., Cincinnati Eye Institute “Real-World Outcomes of Intranasal Varenicline for the Treatment of Dry Eye Disease” – Amar Shah, M.D., Cincinnati Eye Institute “Sterile and Infectious Infiltrates after Epithelial Defect Treatment with Cryopreserved and Dehydrated Amniotic Membrane: A Case Series” – John D. Sheppard, M.D., Virginia Eye Consultants “Refractive impact of topical meds” – Kavitha Sivaraman, M.D., Cincinnati Eye Institute “IC-001 The Wonderful World of Iris Prostheses: A Case-Based Compendium” – Michael Snyder, M.D., Cincinnati Eye Institute “Eyeninja - Danger in the Dark: Introducing the Eidolon Handheld Slit Beam” – Lawrence Tenkman, M.D., John-Kenyon Eye Centers “Can't Touch That!” – Megan Tuohy, M.D., Cincinnati Eye Institute, Michael Snyder, M.D., Cincinnati Eye Institute “Effectiveness of Femtosecond Laser Assisted Cataract Surgery and Manual Phacoemulsification during the Learning Curve of Fellows in Training” – Robert Weinstock, M.D., Eye Institute of West Florida “Safety & Efficacy of Lotilaner Ophthalmic Solution, 0.25% in Treating Demodex Blepharitis: Combined Analysis of Two Pivotal Trials” – Elizabeth Yeu, M.D., Virginia Eye Consultants “CSF-1 (0.4% Pilocarpine HCl Ophthalmic Solution) for the Treatment of Presbyopia: Near-1 and Near-2 Phase 3 Clinical Trials” – Edward J. Holland, M.D., Cincinnati Eye Institute “Effects of Uncrosslinking Ocular Rigidity in Aging Eyes: Rejuvenation of Visual Age Utilizing a New Microporation Therapy” – Elizabeth Yeu, M.D., Virginia Eye Consultants “Prospective, Randomized, Contralateral Eye Study of Femtosecond Laser Assisted Cataract Surgery and Manual Phacoemulsification” – Robert Weinstock, M.D., Eye Institute of West Florida “Interim Assessment of Safety & Efficacy of Human Corneal Endothelial Cell Therapy for Corneal Edema Secondary to Endothelial Dysfunction” – Elizabeth Yeu, M.D., Virginia Eye Consultants “Efficiency of a water-free topical cyclosporine in the treatment of dry eye disease (DED) in patients with or without cataract” – John D. Sheppard, M.D., Virginia Eye Consultants “Changes in Creatinine Levels Related to Tacrolimus Used for Ocular Surface Stem Cell Transplantation” – Albert Y. Cheung, M.D., Virginia Eye Consultants About EyeCare Partners EyeCare Partners is the nation’s leading provider of clinically integrated eye care. Our national network of over 300 ophthalmologists and 700 optometrists provides a lifetime of care to our patients with a mission to enhance vision, advance eye care and improve lives. Based in St. Louis, Missouri, over 700 ECP-affiliated practice locations provide services that span the eye care continuum in 18 states and 30 markets. For more information, visit and follow us on LinkedIn.

DUBLIN, March 6, 2023 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) today reported financial results for the fourth-quarter ended December 31, 2022. FOURTH-QUARTER FINANCIAL PERFORMANCE (in thousands, except per share amounts) CONSOLIDATED FINANCIAL RESULTS Total revenues were $556 million in fourth-quarter 2022, a decrease of 30% compared to $789 million in fourth-quarter 2021. This decrease was primarily attributable to decreased revenues from the Sterile Injectables segment. Reported loss from continuing operations in fourth-quarter 2022 was $245 million compared to $557 million in fourth-quarter 2021. Reported diluted net loss per share from continuing operations in fourth-quarter 2022 was $1.04 compared to $2.38 in fourth-quarter 2021. These results were primarily due to lower asset impairment and litigation-related charges and operating expenses, as well as lower interest as a result of the Chapter 11 filing, partially offset by decreased revenues and expenses related to the Chapter 11 reorganization process. Adjusted income from continuing operations in fourth-quarter 2022 was $190 million compared to $180 million in fourth-quarter 2021. Adjusted diluted net income per share from continuing operations in fourth-quarter 2022 was $0.80 compared to $0.76 in fourth-quarter 2021. These results were primarily driven by lower interest and operating expenses, which were partially offset by decreased revenues. BRANDED PHARMACEUTICALS SEGMENT Fourth-quarter 2022 Branded Pharmaceuticals segment revenues were $224 million, a decrease of 2% compared to $228 million during fourth-quarter 2021. Specialty Products revenues increased 1% to $162 million in fourth-quarter 2022 compared to $161 million in fourth-quarter 2021, with sales of XIAFLEX® decreasing 5% to $114 million compared to $120 million in fourth-quarter 2021. XIAFLEX® fourth-quarter 2022 revenues were unfavorably impacted by continued challenging market conditions for specialty product office-based elective procedures and the ongoing impact from the third-quarter disruption experienced by our third-party specialty pharmacy provider, which improved during fourth-quarter 2022. Established Products revenues decreased 9% to $61 million in fourth-quarter 2022 compared to $67 million in fourth-quarter 2021, driven primarily by ongoing generic competition. STERILE INJECTABLES SEGMENT Fourth-quarter 2022 Sterile Injectables segment revenues were $108 million, a decrease of 66% compared to $319 million during fourth-quarter 2021. This was primarily attributable to decreased VASOSTRICT® revenues due to lower price and market share resulting from generic competition and lower overall market volumes as COVID-19-related hospitalizations decline. GENERIC PHARMACEUTICALS SEGMENT Fourth-quarter 2022 Generic Pharmaceuticals segment revenues were $205 million, a decrease of 6% compared to $218 million during fourth-quarter 2021. This decrease was primarily attributable to competitive pressure on certain generic products, partially offset by revenues from varenicline tablets, the first generic version of Chantix® which launched during third-quarter 2021. INTERNATIONAL PHARMACEUTICALS SEGMENT Fourth-quarter 2022 International Pharmaceuticals segment revenues were $20 million, a decrease of 19% compared to $24 million during fourth-quarter 2021. This decrease was primarily attributable to competitive pressures and the expiration of a product agreement. CASH, CASH FLOW AND OTHER UPDATES As of December 31, 2022, the Company had approximately $1.0 billion in unrestricted cash. Fourth-quarter 2022 net cash provided by operating activities was approximately $110 million compared to approximately $50 million used in operating activities during fourth-quarter 2021. This increase was primarily attributable to a decrease in net working capital as well as reductions in cash interest and litigation related payments, which were partially offset by a decrease in Adjusted EBITDA. Additionally, during fourth-quarter 2022, the Company announced that it will cease the production and sale of Endo Aesthetics' Qwo® (collagenase clostridium histolyticum-aaes) in light of market concerns about the extent and variability of bruising following initial treatment as well as the potential for prolonged skin discoloration. Chantix® is a registered trademark of Pfizer Inc. FINANCIAL SCHEDULES The following table presents Endo's unaudited Total revenues, net for the three months and years ended December 31, 2022 and 2021 (dollars in thousands): The following table presents unaudited Condensed Consolidated Statement of Operations data for the three months and years ended December 31, 2022 and 2021 (in thousands, except per share data): The following table presents unaudited Condensed Consolidated Balance Sheet data at December 31, 2022 and December 31, 2021 (in thousands): The following table presents unaudited Condensed Consolidated Statement of Cash Flow data for the years ended December 31, 2022 and 2021 (in thousands): SUPPLEMENTAL FINANCIAL INFORMATION To supplement the financial measures prepared in accordance with U.S. generally accepted accounting principles (GAAP), the Company uses certain non-GAAP financial measures. For additional information on the Company's use of such non-GAAP financial measures, refer to Endo's Current Report on Form 8-K furnished today to the U.S. Securities and Exchange Commission, which includes an explanation of the Company's reasons for using non-GAAP measures. The tables below provide reconciliations of certain of the Company's non-GAAP financial measures to their most directly comparable GAAP amounts. Refer to the "Notes to the Reconciliations of GAAP and Non-GAAP Financial Measures" section below for additional details regarding the adjustments to the non-GAAP financial measures detailed throughout this Supplemental Financial Information section. As previously communicated, in response to views expressed by the U.S. Securities and Exchange Commission, the Company has, effective January 1, 2022, revised its definition of its adjusted financial measures to no longer exclude Acquired in-process research and development charges (representing the research and development costs it had previously labeled as "Upfront and milestone payments to partners"). As a result of this change, the Company's adjusted financial measures now reflect the impact of those transactions. The inclusion of the impact of these transactions, which may occur from time to time, could result in significant, but temporary, fluctuations in both Endo's GAAP and Non-GAAP financial measures in the period(s) in which they are incurred. These charges also are not indicative of the underlying performance of Endo's operations during the period. This change was applied retrospectively to all periods presented herein. Refer to footnote (15) in the "Notes to the Reconciliations of GAAP and Non-GAAP Financial Measures" section below for additional discussion. Reconciliation of EBITDA and Adjusted EBITDA (non-GAAP) The following table provides a reconciliation of Net loss (GAAP) to Adjusted EBITDA (non-GAAP) for the three months and years ended December 31, 2022 and 2021 (in thousands): Reconciliation of Adjusted Income from Continuing Operations (non-GAAP) The following table provides a reconciliation of the Company's Loss from continuing operations (GAAP) to Adjusted income from continuing operations (non-GAAP) for the three months and years ended December 31, 2022 and 2021 (in thousands): Reconciliation of Other Adjusted Income Statement Data (non-GAAP) The following tables provide detailed reconciliations of various other income statement data between the GAAP and non-GAAP amounts for the three months and years ended December 31, 2022 and 2021 (in thousands, except per share data): Notes to the Reconciliations of GAAP and Non-GAAP Financial Measures Notes to certain line items included in the reconciliations of the GAAP financial measures to the non-GAAP financial measures for the three months and years ended December 31, 2022 and 2021 are as follows: Non-GAAP Financial Measures The Company utilizes certain financial measures that are not prescribed by or prepared in accordance with accounting principles generally accepted in the U.S. (GAAP). These non-GAAP financial measures are not, and should not be viewed as, substitutes for GAAP net income and its components and diluted net income per share amounts. Despite the importance of these measures to management in goal setting and performance measurement, the company stresses that these are non-GAAP financial measures that have no standardized meaning prescribed by GAAP and, therefore, have limits in their usefulness to investors. Because of the non-standardized definitions, non-GAAP adjusted EBITDA and non-GAAP adjusted net income from continuing operations and its components (unlike GAAP net income from continuing operations and its components) may not be comparable to the calculation of similar measures of other companies. These non-GAAP financial measures are presented solely to permit investors to more fully understand how management assesses performance. Investors are encouraged to review the reconciliations of the non-GAAP financial measures used in this press release to their most directly comparable GAAP financial measures. However, the Company does not provide reconciliations of projected non-GAAP financial measures to GAAP financial measures, nor does it provide comparable projected GAAP financial measures for such projected non-GAAP financial measures. The Company is unable to provide such reconciliations without unreasonable efforts due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliations, including adjustments that could be made for asset impairments, contingent consideration adjustments, legal settlements, gain / loss on extinguishment of debt, adjustments to inventory and other charges reflected in the reconciliation of historic numbers, the amounts of which could be significant. See Endo's Current Report on Form 8-K furnished today to the U.S. Securities and Exchange Commission for an explanation of Endo's non-GAAP financial measures. About Endo Endo (OTC: ENDPQ) is a specialty pharmaceutical company committed to helping everyone we serve live their best life through the delivery of quality, life-enhancing therapies. Our decades of proven success come from passionate team members around the globe collaborating to bring treatments forward. Together, we boldly transform insights into treatments benefiting those who need them, when they need them. Learn more at or connect with us on LinkedIn. Cautionary Note Regarding Forward-Looking Statements Certain information in this press release may be considered "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and any applicable Canadian securities legislation, including, but not limited to, statements with respect to financial guidance, the restructuring support agreement and the sale transaction, the Chapter 11 proceedings and recognition proceedings, and any other statements that refer to Endo's expected, estimated or anticipated future results or that do not relate solely to historical facts. Statements including words or phrases such as "believe," "expect," "anticipate," "intend," "estimate," "plan," "will," "may," "look forward," "intend," "guidance," "future," "potential" or similar expressions are forward-looking statements. All forward-looking statements in this communication reflect the Company's current views as of the date of this communication about its plans, intentions, expectations, strategies and prospects, which are based on the information currently available to it and on assumptions it has made. Actual results may differ materially and adversely from current expectations based on a number of factors, including, among other things, the following: the timing, impact or results of any pending or future litigation, investigations, proceedings or claims, including opioid, tax and antitrust related matters; actual or contingent liabilities; settlement discussions or negotiations; the Company's liquidity, financial performance, cash position and operations; the Company's strategy; risks and uncertainties associated with Chapter 11 proceedings; the negative impacts on the Company's businesses as a result of filing for and operating under Chapter 11 protection; the time, terms and ability to confirm a sale of the Company's businesses under Section 363 of the U.S. Bankruptcy Code; the adequacy of the capital resources of the Company's businesses and the difficulty in forecasting the liquidity requirements of the operations of the Company's businesses; the unpredictability of the Company's financial results while in Chapter 11 proceedings; the Company's ability to discharge claims in Chapter 11 proceedings; negotiations with the holders of the Company's indebtedness and its trade creditors and other significant creditors; risks and uncertainties with performing under the terms of the restructuring support agreement and any other arrangement with lenders or creditors while in Chapter 11 proceedings; the Company's ability to conduct business as usual; the Company's ability to continue to serve customers, suppliers and other business partners at the high level of service and performance they have come to expect from the Company; the Company's ability to continue to pay employees, suppliers and vendors; the ability to control costs during Chapter 11 proceedings; adverse litigation; the risk that the Company's Chapter 11 Cases may be converted to cases under Chapter 7 of the Bankruptcy Code; the Company's ability to secure operating capital; the Company's ability to take advantage of opportunities to acquire assets with upside potential; the Company's ability to execute on its strategic plan to pursue, evaluate and close an asset sale of the Company's businesses pursuant to Section 363 of the U.S. Bankruptcy Code; the impact of competition, including competition with VASOSTRICT® and varenicline tablets; Endo's ability to satisfy judgments or settlements or pursue appeals including bonding requirements; Endo's ability to adjust to changing market conditions; Endo's ability to attract and retain key personnel; supply chain interruptions or difficulties; changes in competitive or market conditions; changes in legislation or regulatory developments; Endo's ability to obtain and maintain adequate protection for Endo's intellectual property rights; the timing and uncertainty of the results of both the research and development and regulatory processes, including regulatory decisions, product recalls, withdrawals and other unusual items; domestic and foreign health care and cost containment reforms, including government pricing, tax and reimbursement policies; technological advances and patents obtained by competitors; the performance, including the approval, introduction, and consumer and physician acceptance of new products and the continuing acceptance of currently marketed products; Endo's ability to integrate any newly acquired products into Endo's portfolio and achieve any financial or commercial expectations; the impact that known and unknown side effects may have on market perception and consumer preference for Endo's products; the effectiveness of advertising and other promotional campaigns; the timely and successful implementation of any strategic initiatives; unfavorable publicity regarding the misuse of opioids; the uncertainty associated with the identification of and successful consummation and execution of external corporate development initiatives and strategic partnering transactions; Endo's ability to advance its strategic priorities, develop its product pipeline and continue to develop the market for XIAFLEX® and other branded and unbranded products; and Endo's ability to obtain and successfully manufacture, maintain and distribute a sufficient supply of products to meet market demand in a timely manner. In addition, U.S. and international economic conditions, including consumer confidence and debt levels, inflation, taxation, changes in interest and currency exchange rates, international relations, capital and credit availability, the status of financial markets and institutions, the impact of and response to the ongoing COVID-19 pandemic and the impact of continued economic volatility, can materially affect Endo's results. Therefore, the reader is cautioned not to rely on these forward-looking statements. Endo expressly disclaims any intent or obligation to update these forward-looking statements, except as required to do so by law. Additional information concerning risk factors, including those referenced above, can be found in press releases issued by Endo, as well as Endo's public periodic filings with the U.S. Securities and Exchange Commission and with securities regulators in Canada, including the discussion under the heading "Risk Factors" in Endo's most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q or other filings with the U.S. Securities and Exchange Commission. Copies of Endo's press releases and additional information about Endo are available at or you can contact the Endo Investor Relations Department at [email protected]. SOURCE Endo International plc